CLINICAL PRACTICEOverview of azathioprine treatment in multiple sclerosis
References (27)
- et al.
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone
Clin Neurol Neurosurg
(1975) - et al.
Azathioprine in treatment of multiple sclerosis: final results of a 4½-year controlled study of its effectiveness covering 115 patients
J Neurol Sci
(1982) Double-masked trial of azathioprine in multiple sclerosis
Lancet
(1988)Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
Am J Med
(1985)Why do we need systematic overviews of randomised trials?
Stat Med
(1987)- et al.
Immunological treatment for multiple sclerosis
Lancet
(1989) The disability status scale for multiple sclerosis: apologia for DSS sua
Neurology
(1989)- et al.
Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis
Ann NY Acad Sci
(1965) - et al.
Intensive immunosuppression in progressive multiple sclerosis: a randomised three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH
N Engl J Med
(1983) - et al.
Some aspects of natural history of disseminated sclerosis
QJ Med
(1952)
An illness severity score for multiple sclerosis
Neurology
(1984)
Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo
Final report. Neurology
(1970)
Therapie der multiplen Sclerose mit Levamisol und Azathioprin—Vergleich der Wirksamkeit einer "immunstimulierenden" und "immun-suppressiven" Behandlung
Nervenarzt
(1978)
Cited by (242)
The 20-year history: Change of multiple sclerosis patient profile over 20 years
2019, Multiple Sclerosis and Related DisordersCitation Excerpt :Multiple sclerosis (MS) has for years been one of the most intensively studied neurological diseases in terms of both etiopathogenesis and therapeutic options, and in which perhaps the greatest progress has been made. Until 1993, the treatment of MS consisted of alternatives such as corticosteroid, azathioprine, and ACTH (Von Reis et al., 1953; Yudkin et al., 1991), of which only corticosteroid continues to be effectively employed today. The conclusion of the phase 3 interferon beta 1b study, one potential option in disease progression and MRI activity and progression, other than attack treatment, and its entry into therapeutic use occurred in 1993.
Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together
2014, Journal of the Neurological SciencesTreatment of multiple sclerosis
2011, MedicineAnimal models of multiple sclerosis-Potentials and limitations
2010, Progress in Neurobiology
Copyright © 1991 Published by Elsevier Ltd.